Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity

Abstract

The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.

1 - 9 . (canceled)  
     
     
         10 . A method for the treatment or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity to a patient in need thereof.  
     
     
         11 . The method according to  claim 10 , wherein the inhibitor is a small molecule.  
     
     
         12 . The method according to  claim 10 , wherein the inhibitor is a nucleic acid.  
     
     
         13 . The method according to  claim 10 , wherein the inhibitor is an antibody or a functionally active antibody fragment or derivative.  
     
     
         14 . The method according to  claim 13 , wherein the antibody or antibody fragment is monoclonal, polyclonal, chimeric, humanized or bispecific.  
     
     
         15 . The method according to  claim 13  wherein the antibody fragment is a Fab, Fab′, F(ab′) 2 , scFv or epitope binding fragment.  
     
     
         16 . The method according to  claim 13  wherein the antibody or antibody fragment is conjugated to one or more effector molecule(s).  
     
     
         17 . The method according to  claim 13  wherein the antibody or antibody fragment binds to IL-17.  
     
     
         18 . The method according to  claim 13  wherein the antibody or antibody fragment binds to IL-17R.  
     
     
         19 . The method according to  claim 10  wherein the inhibitor of IL-17 activity is administered in combination with one or more other therapeutically active compounds.